[Elsevier] Targeting TDP-43 in ALS: Regulatory hurdles, trial design deficiencies, and the causal evidence gap for CTx1000 |
|
This post will be closed automatically in 2026-08-06 08:50
Best Answer
1 hour(s) ago
|
| |
10
The transition to life outside the womb: a review of neonatal physiology
30
One-pot synthesis, spectral characterization, biological evaluation, molecular docking studies and in silico ADME/Tox profiling of new 2,4,5 triaryl imidazole derivatives as anti tubercular agents
10
One-pot synthesis, spectral characterization, biological evaluation, molecular docking studies and in silico ADME/Tox profiling of new 2,4,5 triaryl imidazole derivatives as anti tubercular agents
10
Hyperuricemia and prevention of cardiometabolic disease: Unexplored is not unexpected
10
Correcting hyponatremia: how slow should we go?
